[{"address1": "1359 Broadway", "address2": "Suite 1710", "city": "New York", "state": "NY", "zip": "10018", "country": "United States", "phone": "212 433 3791", "website": "https://zentalis.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its product candidates include ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, for the treatment of advanced solid tumors and hematological malignancies. It is in a Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; a Phase 2 clinical trial in Cyclin E1-driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; a Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; a Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, peritoneal, or fallopian tube cancer; a Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; a Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and a Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's product pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; and Dana-Farber. The company was incorporated in 2014 and is headquartered in New York, New York.", "fullTimeEmployees": 166, "companyOfficers": [{"maxAge": 1, "name": "Ms. Julie M. Eastland M.B.A.", "age": 60, "title": "CEO, President & Director", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 397085, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Andrea  Paul J.D.", "age": 43, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2024, "totalPay": 733005, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Vincent A. Vultaggio", "age": 40, "title": "SVP of Finance & Principal Accounting Officer", "yearBorn": 1984, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Wendy  Chang", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kimberly  Freeman", "title": "Chief Strategy Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ingmar  Bruns M.D., Ph.D.", "age": 49, "title": "Chief Medical Officer", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Haibo  Wang", "title": "Chief Business Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.24, "open": 1.22, "dayLow": 1.19, "dayHigh": 1.22, "regularMarketPreviousClose": 1.24, "regularMarketOpen": 1.22, "regularMarketDayLow": 1.19, "regularMarketDayHigh": 1.22, "payoutRatio": 0.0, "beta": 1.809, "forwardPE": -0.33613446, "volume": 776426, "regularMarketVolume": 776426, "averageVolume": 809190, "averageVolume10days": 643770, "averageDailyVolume10Day": 643770, "bid": 1.17, "ask": 1.23, "bidSize": 5, "askSize": 6, "marketCap": 86342288, "fiftyTwoWeekLow": 1.01, "fiftyTwoWeekHigh": 13.0, "priceToSalesTrailing12Months": 3.2139323, "fiftyDayAverage": 1.4164, "twoHundredDayAverage": 2.58615, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -203950672, "profitMargins": 0.0, "floatShares": 49936081, "sharesOutstanding": 71951904, "sharesShort": 5824182, "sharesShortPriorMonth": 4769777, "sharesShortPreviousMonthDate": 1743379200, "dateShortInterest": 1745971200, "sharesPercentSharesOut": 0.0809, "heldPercentInsiders": 0.13387999, "heldPercentInstitutions": 0.80347997, "shortRatio": 6.94, "shortPercentOfFloat": 0.1011, "impliedSharesOutstanding": 71951904, "bookValue": 4.105, "priceToBook": 0.29232645, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -224186000, "trailingEps": -3.14, "forwardEps": -3.57, "enterpriseToRevenue": -7.592, "enterpriseToEbitda": 1.023, "52WeekChange": -0.89881957, "SandP52WeekChange": 0.09362543, "quoteType": "EQUITY", "currentPrice": 1.2, "targetHighPrice": 10.0, "targetLowPrice": 2.2, "targetMeanPrice": 5.85556, "targetMedianPrice": 6.0, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 332452992, "totalCashPerShare": 4.62, "ebitda": -199292992, "totalDebt": 42160000, "quickRatio": 6.726, "currentRatio": 6.937, "totalRevenue": 26865000, "debtToEquity": 14.273, "revenuePerShare": 0.377, "returnOnAssets": -0.26622, "returnOnEquity": -0.59454, "grossProfits": 26865000, "freeCashflow": -79273248, "operatingCashflow": -151522000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -7.4639897, "financialCurrency": "USD", "symbol": "ZNTL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Zentalis Pharmaceuticals, Inc.", "longName": "Zentalis Pharmaceuticals, Inc.", "exchange": "NGM", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "esgPopulated": false, "messageBoardId": "finmb_647536411", "market": "us_market", "marketState": "CLOSED", "exchangeTimezoneName": "America/New_York", "corporateActions": [], "postMarketTime": 1748037182, "regularMarketTime": 1748030400, "regularMarketChangePercent": -3.2258034, "regularMarketPrice": 1.2, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1585920600000, "cryptoTradeable": false, "postMarketChangePercent": 0.833332, "postMarketPrice": 1.21, "postMarketChange": 0.00999999, "regularMarketChange": -0.03999996, "regularMarketDayRange": "1.19 - 1.22", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 809190, "fiftyTwoWeekLowChange": 0.19000006, "fiftyTwoWeekLowChangePercent": 0.18811888, "fiftyTwoWeekRange": "1.01 - 13.0", "fiftyTwoWeekHighChange": -11.8, "fiftyTwoWeekHighChangePercent": -0.9076923, "fiftyTwoWeekChangePercent": -89.88196, "earningsTimestamp": 1747253101, "earningsTimestampStart": 1754569800, "earningsTimestampEnd": 1754915400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.14, "epsForward": -3.57, "epsCurrentYear": -2.21, "priceEpsCurrentYear": -0.54298645, "fiftyDayAverageChange": -0.21639991, "fiftyDayAverageChangePercent": -0.15278164, "twoHundredDayAverageChange": -1.3861499, "twoHundredDayAverageChangePercent": -0.53598976, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.3 - Buy", "displayName": "Zentalis Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-05-24"}]